196 related articles for article (PubMed ID: 16382049)
21. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
Li H; Weinstein IB
Cancer Res; 2006 Dec; 66(23):11399-408. PubMed ID: 17145886
[TBL] [Abstract][Full Text] [Related]
24. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation.
Dias N; Dheur S; Nielsen PE; Gryaznov S; Van Aerschot A; Herdewijn P; Hélène C; Saison-Behmoaras TE
J Mol Biol; 1999 Nov; 294(2):403-16. PubMed ID: 10610767
[TBL] [Abstract][Full Text] [Related]
25. Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.
Jensen LB; Bartlett JM; Witton CJ; Kirkegaard T; Brown S; Müller S; Campbell F; Cooke TG; Nielsen KV
Cancer Biomark; 2009; 5(1):41-9. PubMed ID: 19242061
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
[TBL] [Abstract][Full Text] [Related]
27. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
28. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
29. Targeted inhibition of NMYC by peptide nucleic acid in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis.
Pession A; Tonelli R; Fronza R; Sciamanna E; Corradini R; Sforza S; Tedeschi T; Marchelli R; Montanaro L; Camerin C; Franzoni M; Paolucci G
Int J Oncol; 2004 Feb; 24(2):265-72. PubMed ID: 14719101
[TBL] [Abstract][Full Text] [Related]
30. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
Nakuci E; Mahner S; Direnzo J; ElShamy WM
Exp Cell Res; 2006 Oct; 312(16):3120-31. PubMed ID: 16860316
[TBL] [Abstract][Full Text] [Related]
31. Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
Jia F; Balaji BS; Gallazzi F; Lewis MR
Nucl Med Biol; 2015 Nov; 42(11):809-15. PubMed ID: 26239085
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
[TBL] [Abstract][Full Text] [Related]
33. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1.
Chen C; Chang YC; Liu CL; Chang KJ; Guo IC
Breast Cancer Res Treat; 2006 Jul; 98(2):121-32. PubMed ID: 16752079
[TBL] [Abstract][Full Text] [Related]
34. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.
Fu P; Shen B; Zhao C; Tian G
J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468
[TBL] [Abstract][Full Text] [Related]
35. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
[TBL] [Abstract][Full Text] [Related]
37. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake.
Basu S; Wickstrom E
Bioconjug Chem; 1997; 8(4):481-8. PubMed ID: 9258444
[TBL] [Abstract][Full Text] [Related]
39. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
40. From combinatorial chemistry to cancer-targeting peptides.
Aina OH; Liu R; Sutcliffe JL; Marik J; Pan CX; Lam KS
Mol Pharm; 2007; 4(5):631-51. PubMed ID: 17880166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]